Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) (Descending) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
59676-0303-00 59676-0303 Erythropoietin Procrit 3000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug. 8, 2011 In Use
59676-0303-01 59676-0303 Erythropoietin Procrit 3000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 1, 1989 In Use
59676-0303-02 59676-0303 Erythropoietin Procrit 3000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 1, 1989 Jan. 8, 2014 In Use
59676-0302-00 59676-0302 Erythropoietin Procrit 2000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug. 8, 2011 In Use
59676-0302-01 59676-0302 Erythropoietin Procrit 2000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 1, 1989 In Use
59676-0302-02 59676-0302 Erythropoietin Procrit 2000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 1, 1989 Jan. 8, 2014 In Use
59676-0050-28 59676-0050 Erdafitinib BALVERSA 5.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Oral April 12, 2019 In Use
59676-0040-28 59676-0040 Erdafitinib BALVERSA 4.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Oral April 12, 2019 In Use
59676-0040-56 59676-0040 Erdafitinib BALVERSA 4.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Oral April 12, 2019 In Use
59676-0030-56 59676-0030 Erdafitinib BALVERSA 3.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Oral April 12, 2019 In Use
59676-0030-84 59676-0030 Erdafitinib BALVERSA 3.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Oral April 12, 2019 In Use
59651-0636-03 59651-0636 ISOTRETINOIN ISOTRETINOIN 40.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Jan. 29, 2024 In Use
59651-0635-03 59651-0635 ISOTRETINOIN ISOTRETINOIN 35.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Jan. 29, 2024 In Use
59651-0634-03 59651-0634 ISOTRETINOIN ISOTRETINOIN 30.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Jan. 29, 2024 In Use
59651-0633-03 59651-0633 ISOTRETINOIN ISOTRETINOIN 25.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Jan. 29, 2024 In Use
59651-0632-03 59651-0632 ISOTRETINOIN ISOTRETINOIN 20.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Jan. 29, 2024 In Use
59651-0631-03 59651-0631 ISOTRETINOIN ISOTRETINOIN 10.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Jan. 29, 2024 In Use
59651-0532-03 59651-0532 Erlotinib Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral June 22, 2022 In Use
59651-0532-10 59651-0532 Erlotinib Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral June 22, 2022 In Use
59651-0531-03 59651-0531 Erlotinib Erlotinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral June 22, 2022 In Use
59651-0531-10 59651-0531 Erlotinib Erlotinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral June 22, 2022 In Use
59651-0530-03 59651-0530 Erlotinib Erlotinib 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral June 22, 2022 In Use
59651-0530-10 59651-0530 Erlotinib Erlotinib 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral June 22, 2022 In Use
59651-0523-01 59651-0523 Fosaprepitant dimeglumine Fosaprepitant dimeglumine 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Jan. 12, 2021 In Use
59651-0516-30 59651-0516 Exemestane Exemestane 25.0 mg/1 Hormonal Therapy Aromatase Inhibitor Oral May 20, 2022 In Use

Found 10,000 results in 11 millisecondsExport these results